A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

Abstract Background Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study evaluated the safety, pharma...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kathleen Weisel, Scott Berger, Katie Thorn, Peter C. Taylor, Charles Peterfy, Hilary Siddall, Debra Tompson, Susanne Wang, Emilia Quattrocchi, Susan W. Burriss, Jochen Walter, Paul Peter Tak
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-03-01
coleção:	Arthritis Research & Therapy
Assuntos:	Pharmacokinetics Pharmacodynamics Receptor-interacting protein kinase 1 RIPK1 Rheumatoid arthritis
Acesso em linha:	https://doi.org/10.1186/s13075-021-02468-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!